Literature DB >> 10695687

Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study.

G Palareti1, J Hirsh, C Legnani, C Manotti, A D'Angelo, V Pengo, M Moia, G Guazzaloca, S Musolesi, S Coccheri.   

Abstract

BACKGROUND: Whether elderly patients are at increased risk of complications during oral anticoagulant treatment (OAT) is still a matter of debate.
METHOD: Bleeding and thrombotic events occurring during OAT in 461 patients, aged 75 years or older when they started OAT, and in 461 patients younger than 70 years, matched for sex, OAT indication, and treating center, were examined in a prospective, multicenter, inception-cohort study.
RESULTS: Bleeding rate was 9.9% and 6.6% patient-years in elderly and young patients, respectively (P = .07), and 2.1% and 1.1% for major bleeding (P = .19); 6 and 1 events, respectively, were fatal (all intracranial, relative risk, 6.4; P = .05). In the elderly, bleeding rate was lower (4.5%) for international normalized ratios (INRs) between 2.0 and 2.9; it was higher during the first 90 treatment days (P = .05) and when arterial vascular disease was the indication for OAT (P = .03). Thrombosis rate was 4.2% and 2.5% patient-years in elderly and young patients, respectively (P = .10); however, 13 and 5 events were fatal (relative risk, 2.8; P = .04). Thrombosis rate was lower (1.5%) for INRs between 2.0 and 2.9; it was higher during the first 90 treatment days (P<.001) and 6 of 7 venous events occurred at lower than 2.0 INRs.
CONCLUSIONS: A nonsignificant trend was noted toward a higher rate of both bleeding and thrombotic complications in elderly vs matched younger patients. Intracranial bleeding and fatal thrombotic events were significantly more frequent in the elderly. Our results also indicate that lower than 2.0 INRs do not preclude bleeding in the elderly nor offer adequate protection from thrombotic events. Moderate anticoagulation (2.0-3.0 INRs) in elderly patients seems the safest and most effective.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10695687     DOI: 10.1001/archinte.160.4.470

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  31 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  [Oral anticoagulation and risk of bleeding in elderly patients - the aspect of polypharmacy].

Authors:  Regina E Roller; Bernhard Iglseder; Peter Dovjak; Monika Lechleitner; Ulrike Sommeregger; Ursula Benvenuti-Falger; Ronald Otto; Birgit Böhmdorfer; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2010-06

Review 3.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  [Anticoagulation for stroke prevention. An update].

Authors:  H C Koennecke
Journal:  Nervenarzt       Date:  2007-10       Impact factor: 1.214

5.  EUS and ERCP complication rates are not increased in elderly patients.

Authors:  Mark E Benson; Siobhan Byrne; Donald J Brust; Bradley Manning; Patrick R Pfau; Terrence J Frick; Mark Reichelderfer; Deepak V Gopal
Journal:  Dig Dis Sci       Date:  2010-02-26       Impact factor: 3.199

6.  [Tools for optimizing pharmacotherapy for geriatric patients with multimorbidity at the end of life: helpful oder just raising awareness?].

Authors:  Renate Riesinger; Bernhard Iglseder
Journal:  Wien Med Wochenschr       Date:  2014-04-09

7.  Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.

Authors:  Eric Pautas; Isabelle Gouin; Oliver Bellot; Jean-Paul Andreux; Virginie Siguret
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 9.  Pharmacologic management of atrial fibrillation in the elderly: rate control, rhythm control, and anticoagulation.

Authors:  Seth McClennen; Peter J Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2003-09       Impact factor: 2.931

Review 10.  Use of anticoagulants in elderly patients: practical recommendations.

Authors:  Helia Robert-Ebadi; Grégoire Le Gal; Marc Righini
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.